In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Single APT vs. dual APT short after PCI

Resources by topic selected by ACVC

Introduction of the Expert

An early switch from dual antiplatelet therapy (DAPT) to single antiplatelet therapy (SAPT) up to 3 (-6) months after PCI has been so far the domain in patients with high-bleeding risk (HBR) and is supported in the recent ESC Clinical Practice Guidelines.

This recommendation, however, was based so far on few randomised trials performed in mixed-patient cohorts including HBR and non-HBR as well as ACS and stable patients with coronary artery disease.

Based on an individual patient-level meta-analysis it seems that shorter DAPT (1-3 months) followed by SAPT (by use of a P2Y12-inhibitor) dramatically reduces BARC defined bleedings without a significant impact on combined ischemic outcomes. Data obtained from recent trials (MASTERDAPT, STOP DAPT-2 ACS) add to a better understanding and might have an impact on future guideline updates.


huber-kurt-2013.jpgProf.  Kurt Huber
Interventional cardiologist

Vienna, Austria


Otilia Tica.jpgThe resources below have been selected by Dr. Otilia Čšica, MD, PhD in Cardiology

ACVC Young Member


ESC e-Learning Platform (ESCeL)

escel-acca.jpgAccess a relevant course in the field:

  • Topic 47. Non-ST-elevation Acute Coronary Syndromes


European Heart Journal - Acute Cardiovascular Care

EHJ-ACVC-2021.jpgAccess a selection of relevant scientific papers in the field:


ESC Clinical Practice Guidelines

ACVC Webinars